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Glasgow, UKA B S T R A C TObjectives: To compare different chronic obstructive pulmonary dis-
ease (COPD) cost-effectiveness models with respect to structure and
input parameters and to cross-validate the models by running the
same hypothetical treatment scenarios. Methods: COPD modeling
groups simulated four hypothetical interventions with their model
and compared the results with a reference scenario of no interven-
tion. The four interventions modeled assumed 1) 20% reduction in
decline in lung function, 2) 25% reduction in exacerbation frequency,
3) 10% reduction in all-cause mortality, and 4) all these effects
combined. The interventions were simulated for a 5-year and lifetime
horizon with standardization, if possible, for sex, age, COPD severity,
smoking status, exacerbation frequencies, mortality due to other
causes, utilities, costs, and discount rates. Furthermore, uncertainty
around the outcomes of intervention four was compared. Results:
Seven out of nine contacted COPD modeling groups agreed to
participate. The 5-year incremental cost-effectiveness ratios (ICERs)ee front matter Copyright & 2014, International S
r Inc.
1016/j.jval.2014.03.1721
oorn@bmg.eur.nl.
ondence to: Martine Hoogendoorn, Institute for Me
, The Netherlands.for the most comprehensive intervention, intervention four, was
€17,000/quality-adjusted life-year (QALY) for two models, €25,000 to
€28,000/QALY for three models, and €47,000/QALY for the remaining
two models. Differences in the ICERs could mainly be explained by
differences in input values for disease progression, exacerbation-
related mortality, and all-cause mortality, with high input values
resulting in low ICERs and vice versa. Lifetime results were mainly
affected by the input values for mortality. The probability of inter-
vention four to be cost-effective at a willingness-to-pay value of
€50,000/QALY was 90% to 100% for ﬁve models and about 70% and
50% for the other two models, respectively. Conclusions: Mortality
was the most important factor determining the differences in cost-
effectiveness outcomes between models.
Keywords: COPD, cost-effectiveness, model, validation.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Chronic obstructive pulmonary disease (COPD) is a chronic
condition characterized by persistent airﬂow limitation that is
usually progressive and associated with an enhanced chronic
inﬂammatory response in the airways and the lungs to noxious
particles or gases [1]. Most important respiratory symptoms are
cough, sputum production, and dyspnea. Patients regularly expe-
rience exacerbations, which are periods of increased symptoms,
often leading to increased use of health care, hospital admission,
or even death [2–6]. Prevalence estimates of COPD are as high as11.4% to 26.1% for the population older than 40 years [7]. COPD is
associated with a signiﬁcant impairment of quality of life and
substantial health care use, especially in the more severe stages
[8]. The Global Burden of Disease study 2010 showed that COPD is
the third leading cause of death and the ninth cause of disability-
adjusted life-years worldwide [9,10]. In most Western countries,
age-speciﬁc prevalence rates are stable or decreasing in men but
increasing in women. Because of aging of the population, the
absolute number of patients is still expected to increase substan-
tially in the coming decade. COPD is projected to be the ﬁfth
leading cause of disability worldwide in 2030 [11]. This putsociety for Pharmacoeconomics and Outcomes Research (ISPOR).
dical Technology Assessment, Erasmus University, P.O. Box 1738,
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already rising by 4% each year in European countries [12]. It also
puts pressure on the limited capacity of pulmonary hospital
wards. Against this background, information on the cost-
effectiveness of the increasing number of treatment options for
COPD becomes more and more important to guide reimburse-
ment decision making. Such information can be obtained from
clinical trials. But in a slowly progressing disease such as COPD,
these trial data are often complemented with cost-effectiveness
models that facilitate extrapolation of trial data to a longer time
horizon and comparisons between treatments that have not been
compared head-to-head in a clinical trial.
In the last decade, several cost-effectiveness models for COPD
were published. Inspired by the Mount Hood Challenge Meetings for
diabetes modelers, the authors M.H., T.F., and M.R. took the initiative
to organize a round-the-table meeting in 2011 for COPD modeling
groups to present their model, discuss data availability, and share
their experience. A secondmeeting focusing on cross-validation was
organized in 2012. The different modeling groups were asked to run
the same prespeciﬁed hypothetical interventions with their model
after standardizing (part of) the input parameters. This way the
effect of differences in input variables and/or assumptions between
the models was investigated. Such cross-validation is one of the ﬁve
main types of model validation as described by the ISPOR-SMDM
Modeling Good Research Practices Task Force [13].
The aim of this article was to compare different COPD models
with respect to structure, input parameters, and implementation
and to cross-validate the models by running hypothetical treat-
ment scenarios. This contributes to a better understanding of the
effect of different modeling choices on the outcomes.Methods
Early in 2012, a steering committee of six people experienced in
COPD modeling was formed (M.R., T.F., A.B., S.B., A.L., and S.S.).
The main task of this committee was to prepare the second
modeling meeting (i.e., date, location), discuss the content of the
treatment scenarios (i.e., standardization of input parameters,
type of interventions), and discuss the current article. In May
2012, several COPD modeling groups were contacted to explore
their interest in participating in the second COPD modeling
meeting and in running the treatment scenarios with their
models. Modeling groups were requested to complete two parts.
First, the groups were asked to simulate four hypothetical
interventions and compare the results with the situation in
which no intervention would have been provided. The second
part focused on the types of uncertainty included in the model
and the uncertainty around the outcomes of the fourth inter-
vention. Data were reported in a structured Microsoft Excel
spreadsheet and returned to the organizers of the meeting 2
weeks before the meeting took place. A structured overview of
the results of the different models was provided to all partic-
ipants during the meeting as input for the discussion. After the
meeting, modeling groups were contacted once or twice to
provide clariﬁcations or to perform additional or re-analyses.
Overview of Participating Models
In total nine comprehensive COPD models were identiﬁed on the
basis of a search in PubMed and through personal communication
with modelers in the ﬁeld [14–22]. In total, seven modeling groups
agreed to participate [14–20]. The model of Spencer et al. [22] did
not participate because the company who funded the work was in
the middle of developing a newmodel. Furthermore, the Burden of
Obstructive Lung Disease model was not represented [21], because
no modelers of this group could be present at the meeting. All theseven participating models were state-transition models and
assumed the Markov property but varied in the number of health
states and the duration of a cycle. One patient-level model was
included [15]. All models used the Global Initiative for Chronic
Obstructive Lung Disease lung function classiﬁcation published in
2003 to deﬁne COPD severity stages [23]. All of them modeled the
incidence of COPD exacerbations, but in different ways. For all but
one model [18], the maximum time horizon was lifetime. A short
description of participating models is given below. Details and
data sources for two important parameters, disease progression
and mortality, are described in Tables 1 and 2, respectively.Indacaterol COPD model (by price represented by Asukai) [14]
The indacaterol COPD model published in 2011 was developed to
estimate the cost-effectiveness of the bronchodilating agent
indacaterol versus other long-acting bronchodilators. The model,
funded by Novartis, could be characterized as a state-transition
cohort model with a cycle length of 3 months and was con-
structed in Microsoft Excel. The model had 13 health states: 4
COPD severity states, each further extended by 2 health states for
a nonsevere and severe exacerbation, and death. The COPD
population at the start was based on two large trials for indaca-
terol and speciﬁed by COPD severity. Disease progression in
terms of lung function decline was derived from the Understand
Potential Long-term Impacts on Function with Tiotropium trial
(Table 1). Mortality was subdivided into COPD-related mortality
and all-cause mortality. Mortality due to exacerbations was not
modeled separately (Table 2). The model was validated by
comparing life expectancy with several epidemiology sources
for COPD, which showed that mortality probabilities in the model
were similar to external data.Swedish generic model of disease history and economic impact
of COPD (represented by Borg) [15]
The Swedish generic model of disease history and economic
impact of COPD was published in 2004 and ﬁnanced by AstraZe-
neca. The main purpose of the model, implemented in Splus 2000
Professional, was to evaluate the cost-effectiveness of new
interventions for COPD. The model has seven health states: one
for mild COPD, two states for moderate, two states for severe, one
state for very severe COPD, and death. The model has two health
states each for moderate and severe COPD because backward
transition is allowed up to one milder health state, but not
further. Exacerbation status was modeled as separate states
within each severity state and subdivided into exacerbation-free,
mild, moderate, and severe exacerbations. The two-dimensional
Markov chain model simulated individual patients using two
different cycle lengths: 1 year for disease progression and mortal-
ity and 1 week for exacerbation status. The model was populated
with data on patients with COPD detected during screening of the
general population in Northern Sweden, the Obstructive Lung
Disease in Northern Sweden studies [24]. Transition probabilities
between COPD severity states and mortality were obtained from
10-year follow-up data from the Obstructive Lung Disease in
Northern Sweden studies and modeled to depend on age, COPD
severity, and exacerbations (Tables 1 and 2). The model used
primary data validated against published sources with satisfac-
tory results. For the present work, the model was restored from
the archive and set up to execute. The optimized version of the
computation engine, however, could not be compiled in the
current computer environment and therefore only a limited
number of patients could be simulated, resulting in poor preci-
sion in the estimates.
Table 1 – Overview disease progression.
Model
representative
Framework Subgroup
speciﬁcations
Transition probability in the ﬁrst
year for a 65-y-old ex-smoking
male patient with moderate
COPD
Asukai et al. [14] Annual decline in lung function of 30 ml/y
obtained from the UPLIFT trial used to
calculate transition probabilities
No subgroup
speciﬁcation in
annual decline
Moderate to severe: 4.3%
Moderate to very severe: 0.1%
Borg et al. [15] Transition probabilities based on the 10-y
follow-up data of the OLIN studies.
1. Base risk
2. Risk related to exacerbations
Transition rates
speciﬁed by COPD
disease severity and
age
Moderate to mild: 5.0%
Moderate to severe: 6.0%
Moderate to very severe: 0%
Hansen et al.
[16]
Transition probabilities adapted from Atsou
et al.: mild/moderate COPD based on the
BOLD cohort, for severe to very severe
adapted from Hoogendoorn et al. (Lung
Health Study)
Transition rates
speciﬁed by age,
smoking status, and
COPD disease severity
Moderate to severe: 8.3%
Moderate to very severe: 0.3%
Hoogendoorn
et al. [17]
Annual decline in lung function obtained from
a re-analysis of the original 5-y data of the
Lung Health Study
Annual decline speciﬁed
by sex, age, smoking
status, and COPD
severity
Moderate to severe: 3.2%
Moderate to very severe: 0%
Rutten-van
Mölken
et al. [18]
First year: Annual decline in lung function as
observed in six tiotropium trials.
No subgroup
speciﬁcation in
annual decline
Moderate to severe: 32%
Moderate to very severe: 6.6%
Years 2–5: Annual decline in lung function of 52
ml/y obtained from the Lung Health Study
applied to the patient population in two
trials to calculate the transition probabilities
Samyshkin
et al. [19]
Annual decline in lung function of 52 ml/y
obtained from the Lung health Study used to
calculate time to transition and transition
probabilities
No subgroup
speciﬁcation in
annual decline
Moderate to severe: 7.0%
Moderate to very severe: 0.4%
Wacker et al.
[20]
Annual decline in lung function for mild/
moderate COPD based on the Lung Health
Study (smokers: 60 ml/y, former smokers: 27
ml/y), for smokers with severe COPD based
on the ISOLDE þ TORCH trials. Decline was
transformed into time to transition and
transition probabilities
Annual decline speciﬁed
by smoking
Moderate to severe: 1.1%
Moderate to very severe: 0.01%
BOLD, Burden of Obstructive Lung Disease; COPD, chronic obstructive pulmonary disease; ISOLDE, Inhaled Steroids in Obstructive Lung
Disease; OLIN, Obstructive Lung Disease in Northern Sweden; TORCH, Towards a Revolution in COPD Health; UPLIFT, Understand Potential
Long-term Impacts on Function with Tiotropium.
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The dynamic cohort COPD model developed in the United States
to evaluate the cost-effectiveness of a broad range of COPD
interventions was not yet published at the time of the modeling
meeting but has been presented during the ISPOR Annual
International Meeting of 2012. The model implemented in Micro-
soft Excel had 16 states: 4 COPD severity stages further subdi-
vided into 3 separate states (stable disease, outpatient or
inpatient managed exacerbations), 3 end-stage treatments (i.e.,
lung rehabilitation, lung volume reduction surgery, and lung
transplantation), and death. The starting population of the model
represents the US COPD population. Disease progression in terms
of transition probabilities to the next severity stage was adapted
from Atsou et al. [25], which uses the Burden of Obstructive Lung
Disease cohort [20], and Hoogendoorn et al. [26] and is speciﬁed
by age and smoking status (Table 1). Health-related quality of life
was mapped from the St. George Respiratory Questionnaire [27].
Mortality was divided into all-cause mortality and mortality
associated with outpatient and inpatient managed exacerbations(Table 2). The model was validated by performing various
internal checks and comparison to the Lung Health Study.Dutch dynamic population COPD progression model
(represented by Hoogendoorn) [17,26,28]
The latest version of the Dutch dynamic population COPD progres-
sion model was published in 2011 and was used to estimate the
cost-effectiveness of a wide range of interventions for COPD. The
model sponsored by the Lung Foundation Netherlands is represen-
tative for the Dutch COPD population. It is a state-transition model
with a cycle length of 1 year and has six main health states: no
COPD, four COPD severity stages, and death. Each stage is further
speciﬁed by sex, 1-year age classes, and smoking status. Moderate
and severe exacerbations are modeled as events within each
severity state. The model is dynamic because it takes into account
changes in the general population due to birth, changes in smoking
behavior, and mortality. Changes in the COPD population over time
are the result of new incidence, changes in smoking behavior,
Table 2 – Overview mortality after standardization for background mortality.
Model
representative
Framework Subgroup speciﬁcations Probability to die in the ﬁrst
year for a 65-y-old ex-smoking
male patient with moderate
COPD
Asukai et al. [14] Total mortality: Total mortality: 2.7%
1. All-cause mortality obtained from death
tables (not adjusted for COPD-speciﬁc deaths)
2. COPD-related mortality
1. Speciﬁed by sex and age
2. Speciﬁed by COPD disease
severity
1. 1.5%
2. 1.2%
Borg et al. [15] Total mortality:
1. Base mortality
2. Mortality related to severe exacerbations
1. Speciﬁed by age and disease
severity
2. Speciﬁed by age and disease
severity
Total mortality: 4.6% (with average
number of severe exacerbations)
Hansen et al.
[16]
Total mortality: Total mortality: 3.6%
1. All-cause mortality from life tables
2. Exacerbation-related mortality: relative risks
applied to all-cause mortality in the general
population associated with moderate and
severe exacerbations by COPD stage
1. All-cause mortality by sex
and age
2. Exacerbation-related
mortality by COPD disease
severity and severity of the
exacerbation
1. 1.5% without exacerbation
2. 2.4% with a moderate
exacerbation
3. 3.15% with a severe exacerbation
Hoogendoorn
et al. [17]
Total mortality: Total mortality: 6.0%
1. Mortality due to other causes including other
smoking-related diseases
2. COPD-attributable mortality excluding
mortality due to exacerbations
3. Exacerbation-related mortality
1. Speciﬁed by sex, age, and
smoking status
2. Speciﬁed by sex, age, and
COPD disease severity
3. Speciﬁed by age
1. 1.5%
2. 2.2%
3. 2.3%
Rutten-van
Mölken
et al. [18]
Total mortality Speciﬁed by COPD disease
severity
Total mortality: 6.6%
Samyshkin
et al. [19]
Total mortality: Total mortality: 2.9%
1. Non–COPD-related mortality
2. Increased COPD-related mortality including a
7.7% case fatality associated with a severe
exacerbation
1. Speciﬁed by sex and age
2. Speciﬁed by COPD disease
severity
1. 1.5%
2. 1.4%
Wacker et al.
[20]
Total mortality: Total mortality: 7.4%
1. Mortality in stable disease
– Background mortality
– COPD-related mortality
2. Mortality associated with severe
exacerbations (surgery and transplantation
o60 y)
1. Speciﬁed by age, COPD
disease severity, and
smoking
2. Speciﬁed by age (and
disease stage, smoking
status for AE mortality)
1. 3.5%
– 1.5%
– 2.0%
2. 3.9%
AE, adverse event; COPD, chronic obstructive pulmonary disease.
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eled as annual decline in lung function speciﬁed by sex, age,
smoking status, and disease severity on the basis of a re-analysis
of the original 5-year Lung Health Study data (Table 1) [26]. Total
mortality consisted of mortality related to severe exacerbations,
other COPD-attributable mortality, and mortality due to other causes
(Table 2). The model was implemented in Mathematica 7 and was
validated by performing several internal checks and by comparing
the results with other models [29].Tiotropium COPD model (represented by Rutten-van Mölken)
[18]
The 5-year version of the tiotropium COPD model was imple-
mented in Excel and published in 2007. The model was developed
to estimate the cost-effectiveness of tiotropium (Boehringer
Ingelheim) versus other bronchodilators. The state-transition
cohort model with a cycle length of 1 month has four health
states: moderate, severe, and very severe COPD and death.
Exacerbations were modeled as events within severity states
Table 3 – Input variables to standardize the refer-
ence scenario.
Variable Value*
Sex Male
Age (y) 65
Smoking status Ex-smoker
COPD disease severity† Moderate COPD (GOLD
guidelines) or a mean FEV1 of
65% predicted
Baseline total exacerbation
frequency by COPD
severity†
0.82 (0.26), 1.17 (0.15), 1.61 (0.06),
2.10 (0.36)
Baseline severe exacerbation
frequency by COPD
†
0.11 (0.14), 0.16 (0.07), 0.22 (0.01),
0.28 (0.13)
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start reﬂected the patient population included in the tiotropium
trials. These were mainly patients with severe and very severe
COPD. The distribution of the lung function of patients with
moderate COPD in this population was located at the severe end
of the lung function range for moderate COPD. Disease progres-
sion in the ﬁrst year was based on data from six tiotropium trials.
Because these trials showed an increase in lung function in the
ﬁrst year in part of the patients, backward transition to a less
severe COPD stage is possible in the ﬁrst year. For the following
years, annual decline in lung function was obtained from the
Lung Health Study (Table 1). Mortality was modeled as all-cause
mortality speciﬁed by COPD severity. Exacerbation-related mor-
tality was not modeled separately (Table 2). One-year model
results were validated against 1-year trial data, resulting in
comparable numbers of exacerbations [30].severity
Mortality due to causes other
than COPD
1.5% (0.23)
Utilities during stable disease
by COPD severity†
0.90 (0.11), 0.787 (0.008), 0.750
(0.0093), 0.647 (0.0241)
Annual costs for treating
stable disease by COPD
severity†
€100 (15), €300 (45), €650 (98),
€1200 (180)
Reduction in baseline utility
due to a moderate
exacerbation
1-mo cycle: 18% (2.7), 3-mo
cycle: 6% (0.9), 1-y cycle: 1.5%
(0.22)
Reduction in baseline utility
due to severe exacerbation
1-mo cycle: 60% (9), 3-mo cycle:
20% (3), 1-y cycle: 5% (0.75)
Costs for a moderate and
severe exacerbation,
respectively
€100 (15), €4000 (600)
COPD, chronic obstructive pulmonary disease; FEV1, forced expira-
tory volume in 1 s; GOLD, Global Initiative for Chronic Obstructive
Lung Disease; SE, standard error.
* Data are mean (SE).
† Four COPD severity stages based on the GOLD guidelines: mild
(FEV1 Z 80% of predicted), moderate (50% r FEV1 o80%), severe
(30% r FEV1 o 50%), and very severe COPD (FEV1 o 30%).Roﬂumilast COPD model (represented by Samyshkin) [19,31,32]
The recently published Roﬂumilast COPD model (2012–2013) was
developed to estimate the cost-effectiveness of roﬂumilast versus
several comparators. The model, whose development was
ﬁnanced by Takeda, was a state-transition cohort-based model
implemented in TreeAge Pro Suite 2009 with a Microsoft Excel
front-end. The structure of the original model included three health
states: severe COPD, very severe COPD, and death; the cycle length
in the model was 1 month. For the purpose of this exercise, the
model was extended with the state “moderate COPD.” Exacerba-
tions are modeled as events that can occur within each of the COPD
severity states, and are speciﬁed as moderate or severe. The
population in the severe and very severe states of the model was
based on the patient population of the long-acting beta agonist-
alone group of two large roﬂumilast trials. Disease progression, that
is, annual decline in lung function, was derived from the Lung
Health Study (Table 1). Mortality was modeled as a combination of
background mortality estimated from the general population from
life tables adjusted to the standardized mortality ratio for COPD and
mortality due to severe exacerbations (Table 2).German comprehensive care COPD model (by Menn,
represented by Wacker) [20]
The German comprehensive care COPD model published in 2012
was developed with ﬁnancial support of the Competence Net-
work Asthma/COPD (Federal Ministry of Education and Research).
The model was implemented in TreeAge Pro 2007. The main
purpose of the cohort model was to evaluate the cost-
effectiveness of COPD interventions in the German context. The
model has seven states: four COPD severity states, one state after
lung volume reduction surgery, one state after lung transplanta-
tion, and death. Cycle length is 3 months. Mild, moderate, and
severe exacerbations are modeled as events within disease
states. Starting point of the simulation is a 45-year-old patient
with mild COPD. Disease progression for mild and moderate
COPD was based on the Lung Health Study speciﬁed by smoking
status. The Inhaled Steroids in Obstructive Lung Disease and
Towards a Revolution in COPD Health trials were used to obtain
estimates of the annual decline in severe COPD in smokers
(Table 1). All-cause mortality was divided into mortality in stable
disease, mortality associated with severe exacerbations, and very
severe COPD mortality associated with surgery and transplanta-
tion (Table 2). Model validation was performed by comparing the
results with observed data: the severity distribution among
smokers and quitters in the Lung Health Study and the total
exacerbation probabilities of the TRISTAN trial.Standardization of the Reference Scenario
To increase comparability among the different models, groups
were requested to run their model for a male patient or cohort
of male patients with moderate COPD, ex-smoking, and aged
65 years. Furthermore, groups were asked to standardize exacer-
bation frequencies, mortality due to other causes, utilities, and
costs (Table 3). The probability distribution for the parameters
used in the probabilistic sensitivity analysis was not standar-
dized. All analyses were performed using a 3% discount rate for
both effects and costs. The probabilities for end-stage treatment
options and mild exacerbations were set to zero if included in the
model. A model simulation with the standardized parameters
was considered the reference scenario.Hypothetical Interventions
Four different interventions reﬂecting the broad range of possible
interventions available for COPD were deﬁned. Effect sizes and
costs were hypothetical and not based on any clinical trial. The
ﬁrst intervention assumed a 20% reduction in annual decline in
lung function or, if this was not possible, a 20% reduction in
transition probabilities between COPD severity stages. Annual
costs for this intervention were assumed to be €200 per patient.
The second intervention assumed a 25% reduction in the total
exacerbation frequency, with annual costs of €400 per patient.
When applying this intervention, groups were asked to keep the
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For intervention three, groups modeled a 10% reduction in total
mortality. Annual costs were €300 per patient. The fourth
intervention consisted of the combination of all three effects of
the ﬁrst three interventions, 20% reduction in annual decline in
lung function, 25% reduction in exacerbation frequency, and 10%
reduction in mortality, with annual costs of €700 per patient.Outcomes
Each modeling group ran the hypothetical interventions for two
different time horizons: 5 year and lifetime. For both time
horizons, groups reported the following outcomes: mean number
of exacerbations per patient, mean number of life-years, quality-
adjusted life-years (QALYs) gained and incremental costs per
patient, and the incremental cost-effectiveness ratio (ICER) com-
pared with the reference scenario. In addition, the severity
distribution over the COPD severity stages after 5 years and the
percentage of patients who died were provided for the 5-year
horizon, while for the lifetime analysis the time spent in each
severity stage was reported.Fig. 1 – Comparison of 5-year model outcomes for the reference
distribution and mortality and (B) mean number of exacerbation
obstructive pulmonary disease; QALYs, quality-adjusted life-yea
Hansen.Uncertainty
For the second part of the exercise, groups provided details about
uncertainty around the outcomes of intervention four, a 20% (SE 4)
reduction in annual decline in lung function, 25% (SE 5) reduction
in exacerbation frequency, and 10% (SE 2) reduction in mortality,
with annual costs of €700 per patient using a 5-year time horizon.
Ninety-ﬁve percent conﬁdence intervals were given around the
mean number of QALYs and mean costs for the intervention and
the usual-care scenario as well as the difference in QALYs and
costs. Furthermore, each modeling group displayed the uncer-
tainty around the outcomes in an acceptability curve with
willingness-to-pay values between €0 and €100,000 per QALY.Results and Explanations
Comparison of Reference Scenario
Five-year model outcomes for the reference scenario after stand-
ardization of requested input parameters are shown in Figure 1.
In ﬁve out of seven models, the percentage of patients still in
moderate COPD after 5 years was around 60% to 70%. In thescenario, discount rate both costs and effects 3%. (A) Severity
s and (quality-adjusted) life-years per patient. COPD, chronic
rs. *Total exacerbations was not an outcome in the model of
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 5 2 5 – 5 3 6 531model of Borg et al., 10% of the patients regressed to mild COPD
and about 55% remained in moderate COPD, while in the model
of Rutten, 20% of the patients remained in moderate COPD and
32% progressed to severe COPD. Further comparison of the seven
models showed that the percentage of patients who died after 5
years ranged from 14% to 31%. The mean number of QALYs
varied between 2.7 and 3.7. The mean 5-year costs per patient for
the models of Asukai, Borg, and Menn/Wacker were around €4000
(range €3743–€4001). For the other four models, the mean costs
varied between €5097 for the model of Samyshkin and €5806 for
the model of Hansen. Differences were larger but comparable in
ranking for a lifetime time horizon (data not shown). Despite the
standardization, the outcomes for the reference scenario still
showed substantial variation between the models, especially
regarding survival.
Intervention One: Disease Progression
For the models of Asukai, Hoogendoorn, and Samyshkin, this
intervention was implemented as a 20% reduction in annual decline
in lung function. The other models applied a 20% reduction in
transition probabilities to worse states. Based on the results, the
effect of altering decline or altering probabilities seemed minimal.
Using a 5-year time horizon, the differences in cost-effectiveness
ratios for intervention one (Table 4) could mainly be explained by
the differences in transition probabilities between the models,
except for the models of Borg and Hansen. In general, models with
high transition probabilities to worse severity stages, such as the
model of Rutten (see Table 1), beneﬁt most from a 20% reduction in
transition probabilities and thus reported the lowest ICERs. In
accordance with this, models with low transition probabilities, such
as the models of Menn/Wacker and Hoogendoorn, found a high
ICER. The model of Hansen et al. found a high ICER in comparison
with other models given the relatively high transition probabilities
(Table 1). The model of Borg reported a very high cost-effectivenessTable 4 – Five-year cost-effectiveness results for the fou
intervention.
Intervention Asukai Borg Hansen H
Intervention one: 20% reduction in disease progression
Difference in QALYs 0.012 0.00020 0.0077
Difference in costs (€) 842 880 912
Cost-effectiveness
ratio (€)
69,000 4,400,500 118,300
Intervention two: 25% reduction in exacerbations
Difference in QALYs 0.018 0.024 0.0089
Difference in costs (€) 1,249 1,350 942
Cost-effectiveness
ratio (€)
68,900 56,000 106,300
Intervention three: 10% reduction in mortality
Difference in QALYs 0.026 0.017 0.045
Difference in
costs (€)
1,431 1,465 1,618
Cost-effectiveness
ratio (€)
55,500 87,200 35,700
Intervention four: combination of effects intervention one to three
Difference in QALYs 0.056 0.10 0.054
Difference in costs (€) 2,608 2,903 2,570
Cost-effectiveness
ratio (€)
46,700 27,800 47,400
QALYs, quality-adjusted life-years.ratio because of a (nearly) zero difference in QALYs, which could be
explained by poor precision due to a small number of simulated
patients, or that some patients spend time in mild COPD in which
there is relatively little disease progression risk to be reduced (thus
little beneﬁt of the intervention) while the cost of the intervention is
still accrued.
Using a lifetime horizon, the ICER is affected by a combination
of the transition probabilities to the next severity stage as well as
the probability of death. The model of Menn/Wacker with a low
transition probability to more severe stages and a high proba-
bility to die found the highest ICER (Table 5) because the absolute
gain in effect is relatively low and the time to gain effect is
relatively short, on average 7.2 life-years. The model of Asukai
with the lowest annual mortality probability reported the most
favorable ICER because the time to gain effect was the longest, on
average 14.8 life-years.
Intervention Two: Exacerbations
Differences in outcomes for intervention two, a 25% reduction in
exacerbation frequency, could mainly be explained by differences
in exacerbation-related mortality. For the 5-year time horizon,
the model of Menn/Wacker and Hoogendoorn both resulted in
low costs per QALY (Table 4) because of the relatively high
mortality associated with exacerbations in comparison with
other models (see Table 2). The models of Asukai and Rutten
reported a high ratio because exacerbations did not have an
impact on mortality, so the gain in the QALYs was the result of a
gain only in quality of life and not in life-years. The model of
Rutten et al. reported a lower ICER than did the model of Asukai
et al. because in the ﬁrst model patients progress faster to a more
severe health state associated with higher exacerbation rates and
therefore higher absolute gains in QALYs compared with the
situation in which patients remain in moderate COPD for a longer
time period. The model of Hansen reported the highest ICER,r hypothetical interventions compared with no
oogendoorn Rutten Samyshkin Wacker
0.0035 0.039 0.018 0.0020
816 561 734 695
234,500 14,400 40,200 347,500
0.056 0.020 0.046 0.075
961 739 926 844
17,300 37,000 20,200 11,300
0.034 0.048 0.025 0.047
1,345 1,315 1,361 1,140
39,300 27,400 55,400 24,300
0.091 0.11 0.086 0.12
2,295 1,854 2,173 2,002
25,300 17,400 25,300 16,800
Table 5 – Lifetime cost-effectiveness results for the four hypothetical interventions compared with no
intervention.
Intervention Asukai Borg Hansen Hoogendoorn Samyshkin Wacker
Intervention one: 20% reduction in disease progression
Difference in QALYs 0.357 0.110 0.083 0.081 0.270 0.030
Difference in costs (€) 1,893 4,051 1,735 1,633 1,591 1,427
Cost-effectiveness ratio (€) 5,300 36,700 21,000 20,100 5,900 47,600
Intervention two: 25% reduction in exacerbations
Difference in QALYs 0.060 0.317 0.087 0.366 0.205 0.382
Difference in costs (€) 2,953 7,917 1,629 2,419 2,113 2,143
Cost-effectiveness ratio (€) 49,500 25,000 18,600 6,600 10,300 5,600
Intervention three: 10% reduction in mortality
Difference in QALYs 0.581 0.255 0.616 0.347 0.259 0.336
Difference in costs (€) 4,211 7,012 5,175 3,463 3,568 2,762
Cost-effectiveness ratio (€) 7,300 27,500 8,400 10,000 13,800 8,200
Intervention four: combination of effects intervention one to three
Difference in QALYs 1.030 0.533 0.714 0.806 0.751 0.755
Difference in costs (€) 6,938 14,579 6,886 6,018 5,595 5,146
Cost-effectiveness ratio (€) 6,700 27,300 10,000 7,500 7,400 6,800
QALYs, quality-adjusted life-years.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 5 2 5 – 5 3 6532which was unexpected given that this model included an
increased mortality risk associated with both moderate and
severe exacerbations. When models were ranked according to
the ICERs for the lifetime time horizon, the ranking was com-
parable to the 5-year time horizon (Table 5).
Intervention Three: All-Cause Mortality
Results of intervention three, a 10% reduction in total mortality,
could be explained by the input values for mortality used in the
models (Table 2). The 5-year results showed that in the models of
Menn/Wacker and Rutten for which mortality probabilities in the
ﬁrst year were the highest, around 7%, a 10% reduction in
mortality probability had the highest impact and therefore the
ICERs were the lowest (Table 4). For the models of Asukai and
Samyshkin with the lowest mortality probabilities, around
3%, the ICERs were the highest. Based on the ranking of the
mortality probabilities in the ﬁrst year, the ICER for the Borg
model was higher than expected when compared with the other
models, while the ICER for the model of Hansen was lower than
expected. Results of the ICERs for the lifetime time horizon
were comparable in ranking to the 5-year results (Table 5), except
for the model of Asukai, which resulted in the lowest ICER
although this model had the lowest mortality probability in the
ﬁrst year.
Intervention Four: Combination of Three Effects
In all models, the three effects of intervention four were not
calibrated. This means that it was not taken into account that, for
example, a reduction in exacerbation frequency already leads to a
reduction in mortality in most models. For the current exercise,
effects of intervention four were implemented independently. As a
result, the gain in QALYs for intervention four was fairly comparable
to the sum of QALYs gained in the ﬁrst three interventions in six out
of seven models. Differences in cost-effectiveness results between
themodels for intervention four are more difﬁcult to explain because
these are the result of simultaneous changes in three different
parameters. Mortality, however, seems to be the driving factor. The
model of Menn/Wacker using the highest values for total mortality
and exacerbation-related mortality but the slowest disease progres-
sion reported the most favorable ICER. The model of Asukai, whichused moderate values for disease progression, the lowest value for
total mortality, and no additional mortality for exacerbations, found
one of the highest ICERs (Table 4).
Uncertainty
A list of parameters for which uncertainty is included in the
models can be found in Appendix I in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2014.03.1721. Figure 2
shows the 95% conﬁdence intervals around the difference in
QALYs and costs for intervention four using a 5-year time
horizon. Figure 3 shows the acceptability curve for intervention
four. Six models showed curves that had roughly the same shape,
with a relatively steep increase in the probability of the inter-
vention being cost-effective. The thresholds at which a 90% cost-
effectiveness probability was reached varied from €30,000 to
€60,000 for these models. The acceptability curve for the model
of Hansen increased very gradually and reached a 90% conﬁdence
level at a €85,000 threshold.Discussion
This cross-model validation study aimed to compare different
COPD models by explaining the results of the evaluation of four
hypothetical interventions that affected lung function decline,
COPD exacerbations, all-cause mortality, or all three of these on
the basis of differences in model structure and input parameters.
Differences in the results of the deterministic analyses could, in
general, be explained by structural uncertainty and by the rank
order of input values used for disease progression, exacerbation-
related mortality, and total mortality in the models. Mortality
was the most important factor determining the QALY outcomes,
especially for a lifetime time horizon. For example, for the
intervention that assumed a 20% reduction in disease progres-
sion, the differences in transition probabilities to more severe
disease states were of less importance for the lifetime results
than the values used as input for total mortality. A substantial
part of the differences in the results of the deterministic analyses
was the result of structural uncertainty in each model. Structural
uncertainty is characterized by assumptions about the structure
Fig. 2 – Uncertainty around the results of intervention four for a 5-year time horizon: mean and 95% conﬁdence intervals
around (A) difference in QALYs and (B) difference in costs. QALYs, quality-adjusted life-years.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 5 2 5 – 5 3 6 533of the model, such as the number of COPD severity states, the
possibility of backward transition to less severe states, and the
inclusion of exacerbation-related mortality [33]. Mortality was
one of the parameters with the most variation in the way it wasFig. 3 – Acceptability curve for intervention four commodeled. Most models speciﬁed mortality into two types: non–
COPD-related mortality and COPD-related mortality. The concept
of non–COPD-related mortality, however, does not mean the
same in all models. Some models deﬁne this as the all-causepared with no intervention, 5-year time horizon.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 5 2 5 – 5 3 6534mortality rate in the general population, whereas other models
deﬁne this as all non–COPD-related mortality among patients
with COPD, including the increased risk to die of other—mostly
smoking-related—diseases (Table 2). In some models, COPD-
related mortality equals exacerbation-related mortality, whereas
in other models exacerbation-related mortality is part of COPD-
related mortality and also includes COPD-attributable mortality
that is not related to exacerbations (Table 2). These differences in
deﬁnition hinder comparison between models with respect to
mortality. These differences also cause the same intervention (e.
g., an intervention that reduces the exacerbation rate with 25%)
to have different mortality effect sizes, depending on the model.
Therefore, it is of utmost importance to aim for consensus on
how mortality is best modeled and what data to use for this.
Modeling mortality from COPD exacerbations separately obvi-
ously leads to more favorable cost-effectiveness ratios of inter-
ventions that reduce the exacerbation rate than not doing so.
When comparing the results of the probabilistic sensitivity
analysis for intervention four, differences result not only from
differences in model structure and input values but also from
parameter uncertainty. Parameter uncertainty results from the fact
that a parameter value is estimated from a sample and the “true”
value is unknown. This uncertainty is represented by a probability
distribution for each parameter [33]. Although the uncertainty
around utilities, costs, COPD exacerbation probabilities, and mortal-
ity from causes other than COPD was standardized by providing a
standard error (SE), the differences in uncertainty around the
estimated difference in QALYs and costs for intervention four were
still substantial. This was probably caused by the uncertainty
around other nonstandardized parameters, such as disease pro-
gression and COPD-related mortality, and/or differences in the type
of probability distributions around parameters used in the proba-
bilistic sensitivity analysis. For example, there is a more than 2-fold
difference between the models in the point estimate of the QALY
gain due to intervention four (from 0.054 to 0.12) and a 14-fold
difference in the width of the 95% conﬁdence interval around the
QALY gain (from 0.011 to 0.151) (Fig. 2). The probability that
intervention four was cost-effective at a threshold value of
€50,000 ranged from 45% to almost 100%.
Differences with regard to structure and input parameters can
often be explained by the model’s purpose. Some of the models
are more universal in the sense that they can be used for a range
of problems, while other models were built for a speciﬁc appli-
cation, for example, the extrapolation of the results of a trial. The
results of the indacaterol model, for example, were mainly
affected by mortality being independent from exacerbations.
The primary end point in the indacaterol trials used as input
for the model was the change in lung function in the ﬁrst
12 weeks. Therefore, less emphasis was put on modeling the
effect of exacerbations on mortality. The results for the tio-
tropium model could mainly be explained by the high disease
progression in this model. In this model, disease progression for
the ﬁrst year was based on data from six trials. These trials
mainly included patients with severe and very severe COPD. The
few patients with moderate COPD (about 20% of all patients in
the original trials) had a forced expiratory volume in 1 second %
predicted close to the cutoff point for severe COPD, resulting in a
high probability to move from moderate to severe COPD. In the
original, nonstandardized version of the model, this fast pro-
gression is compensated by a relatively high probability to move
back from severe to moderate COPD in the ﬁrst year because of
an improvement in lung function in part of the patients after
start of the medication. Because the scenarios described a
moderate patient instead of a patient population with mixed
severity, however, the percentage of patients moving back from
severe to moderate is very small. Moreover, the deﬁnition of the
health states in this model was based on prebronchodilatorforced expiratory volume in 1 second, which increases the
severity of the populations and the probability to move into a
more severe health state. In retrospect, this model seems less
suitable to use for analyses for a cohort of patients with
moderate COPD.
Cross-validation of models may increase conﬁdence in the
results if similar results are found by different models [13]. One
of the limitations of this approach, however, is that ﬁnding
similar results does not mean that results are valid. Agreement
may be the result of using the same structural assumptions
and data sources for input. The Lung Health Study, for exam-
ple, was used as a single or combined data source by ﬁve of the
seven models to estimate disease progression. Another limi-
tation of our current cross-validation exercises is that by
running hypothetical interventions with the models only the
differences between the models can be explained, but not
which models perform best. Although the effectiveness of the
interventions lies within the range of effect sizes observed in
COPD interventions, using hypothetical interventions may also
have reduced the clinical relevance. Real-life data are needed
to further validate the models. During the Mount Hood Chal-
lenge Meetings for diabetes modeling, this was done by per-
forming simulations of outcomes for patients published in
clinical trials [34–36]. Validation against real-life data may be
a topic of future COPD modeling meetings. The availability of
well-performed COPD trials with a follow-up of several years is
however limited [37,38].
To make the results of the treatment scenarios more com-
parable, part of the input parameters was standardized. Models
were asked to run the scenarios for a male, ex-smoking patient
aged 65 years with moderate COPD. All models were able to
standardize for disease severity, exacerbation frequency, util-
ities, and costs. For the model of Hansen, standardization of
exacerbation-related parameters, however, was done differently
than in the other models, because the total number of exacer-
bations was not an outcome in this model, only exacerbation
days. Therefore, the standardized input values for exacerbation
utility decrement and costs were divided by the mean number of
days of an exacerbation and applied as the mean utility decre-
ment or costs per exacerbation day. Standardization with
respect to other parameters was occasionally difﬁcult. The
model of Rutten was not standardized for sex and age and the
model of Borg was not standardized for sex, because these
patient characteristics were not included as model parameters.
Not standardizing for age could have had a large effect, espe-
cially on the results of the lifetime analysis. The maximum time
horizon for the model of Rutten, however, was 5 years. Only
three models [16,17,20] were able to standardize for smoking
status, because smoking status was not considered in the other
models. The model of Hoogendoorn was the only model taking
into account restart rates for smoking. The effect of these restart
rates on the results for the current analyses was minimal; after 5
years, more than 95% of the cohort was still ex-smoker. Finally,
the model of Borg was not able to standardize background
mortality, while in the model of Rutten only all-cause mortality
could be standardized, because this is the only type of mortality
included in this model. The type of mortality that is stand-
ardized, however, seemed of minor importance because total
mortality rates are different between models anyway. The
choice of parameters needing standardization was made by the
steering committee and comprised ﬁnding a balance between
getting comparable results versus maintaining the speciﬁc char-
acter of the models.
The severity distribution for COPD used in all models was
based on the degree of airﬂow limitation. In 2011, the Global
Initiative for Chronic Obstructive Lung Disease committee pro-
posed a new grading of COPD severity based on airﬂow
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 5 2 5 – 5 3 6 535obstruction, exacerbations, and symptoms to better capture the
complexity of COPD. Currently, the prognostic value of this new
classiﬁcation is being investigated [39–41]. Changes in the struc-
ture of the models to this new classiﬁcation need to be consid-
ered if treatment effects and cost-effectiveness results are found
to be different between the different severity classes. This would
also, however, have an effect on the type of model. All models
included in the current article were Markov models. Using more
parameters than lung function alone to deﬁne COPD severity
would increase the number of health states exponentially and
substantially increase the complexity of the model structure as
well the input data required. Current COPD models under devel-
opment or recently published models are therefore exploring
microsimulation modeling or structured equation modeling
[42,43]. The advantage of such approaches is that heterogeneity
of the patient population can be better taken into account in the
model, which is becoming more and more important because
treatment for COPD is increasingly personalized.
In conclusion, this article describes the comparison of seven
cost-effectiveness models for COPD by means of the results of
four hypothetical interventions and tries to explain the differ-
ences in outcomes on the basis of differences in structure and
input data for mortality and disease progression. Mortality was
shown to be the most important factor determining the differ-
ences in cost-effectiveness outcomes. Validation against real-life
data is needed to further validate the models.
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